WaveBreak
Tian Tian is a Senior Scientist at WaveBreak (formerly Wren Therapeutics) with experience as a Postdoctoral Researcher at the University of Cambridge and the University of Edinburgh. Tian Tian holds a Ph.D. in Biomedical Sciences (Integrative Physiology), an M.Sc. by Research in Biomedical Sciences (Life Sciences), and a Bachelor's degree in Biology/Biological Sciences from Fudan University.
This person is not in any offices
WaveBreak
WaveBreak is a biopharmaceutical company focused on transforming drug discovery for neurodegenerative diseases, targeting the fleeting protein intermediates central to many disease pathways that are beyond the reach of conventional drug discovery approaches. WaveBreak has built a unique drug discovery platform to target the transient protein intermediates—the oligomers—in these disease pathways, to interrupt the molecular mechanisms that are the source of oligomer generation with small-molecule therapeutics. WaveBreak is focusing this platform first on some of the greatest unmet medical needs of our time: Parkinson’s disease, Lewy body dementia, Alzheimer’s disease, and ALS.